Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 Research and Markets ... "Spectroscopy Equipment and Accessories - Global ... offering. This report analyzes ... Accessories in US$ Thousands by the following ... Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... and products for advanced microarray diagnostics, today announced it ... 22 at 2:00 pm ET.  During ... a brief review of SQI,s recent commercialization progress and ... industry veteran recently appointed to the Board of Directors ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight is ... HIV infection and the number of deaths due to AIDS ... across the globe. It has been estimated that the death ... 2013, with the rates for children being even much lower. ... rates has been the improved access to antiretroviral drugs and ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Inc. (Amex:,SGN) has received its second Frost & Sullivan ... 2008, at the Frost & Sullivan Awards Banquet,Signalife was ... American Patient Monitoring. Signalife,s Chief Executive Officer, Dr.,Lowell Harmison, ... present to accept the award., Signalife, Inc. is ...
... result in longer-lasting, safer batteries for ... cars, ... Department of Energy,s,(DOE) Argonne National Laboratory and Toda Kogyo Corp. ... commercial production and,sales of Argonne,s patented composite cathode materials for ...
... March 13 Arpida Ltd,(SWX: ARPN) announced today its ... 2007 highlights, Major pipeline progress:, - Second ... its pre-specified primary endpoint, as did the first, ... iclaprim in,cSSSI initiated, - First patients enrolled in ...
Cached Biology Technology:Signalife Wins Second Frost & Sullivan Technology Award 2Signalife Wins Second Frost & Sullivan Technology Award 3Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 2Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 3Arpida Announces Full Year 2007 Financial Results 2Arpida Announces Full Year 2007 Financial Results 3Arpida Announces Full Year 2007 Financial Results 4Arpida Announces Full Year 2007 Financial Results 5Arpida Announces Full Year 2007 Financial Results 6Arpida Announces Full Year 2007 Financial Results 7Arpida Announces Full Year 2007 Financial Results 8Arpida Announces Full Year 2007 Financial Results 9
(Date:8/19/2014)... A team of UTSA researchers has been awarded a ... Technology and Training (NCPTT), an office of the National ... The grant will fund a one-year study of the ... of historic homes in hot, humid climates. , Radiant ... or attics that reflect heat back, thereby reducing the ...
(Date:8/19/2014)... 19, 2014A new ovoid structure discovered in the Nakhla ... a variety of minerals, and shows evidence of undergoing ... of the permafrost and mixing of surface and subsurface ... of analytical studies to determine the origin of this ... this ovoid formed, point to the most likely conclusion, ...
(Date:8/19/2014)... concentrations of African dust transported to South America ... These research findings offer new insight on the ... African dust, including the climate change-induced human health ... African dust emissions in the coming decades., Researchers ... of Marine and Atmospheric Science and colleagues analyzed ...
Breaking Biology News(10 mins):UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3Life on Mars? Implications of a newly discovered mineral-rich structure 2Study of African dust transport to South America reveals air quality impacts 2
... historical water conditions. By synthesizing present-day data with ... trends on a regional basis for periods from which scant ... impede hydrologists, understanding of the current state of waterways and ... was the case for the rivers of the northeastern United ...
... to measure the structure of membrane proteins despite being damaged ... help fast track the development of targeted drugs using emerging ... today depend on the activity of membrane proteins, which are ... our body. A major problem for the design of ...
... crow, a forest crow living on Rota Island in the ... The extinction could happen almost twice as soon as previously ... bird management program that focuses on helping fledgling birds reach ... in psychology. Ha examined survival rates in 97 Mariana ...
Cached Biology News:CCNY-led interdisciplinary team recreates colonial hydrology 2CCNY-led interdisciplinary team recreates colonial hydrology 3Despite damage, membrane protein structure can be seen using new X-ray technology, study reveals 2Without intervention, Mariana crow to become extinct in 75 years 2